Gene Modified T Cell Therapies for Hematological Malignancies

被引：5
|
作者：
Abramowski-Mock, Ulrike [1 ]
Delhove, Juliette M. [1 ]
Qasim, Waseem [1 ]
机构：
[1] UCL, Mol & Cellular Immunol Unit, UCL Great Ormond St Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2017年 / 31卷 / 05期
基金：
“创新英国”项目;
关键词：
Gene therapy; Gene editing; Adoptive immunotherapy; T cell receptor; Chimeric antigen receptor; Lentiviral vectors; Leukemia; Lymphoma; CHIMERIC-ANTIGEN-RECEPTOR; ACUTE MYELOID-LEUKEMIA; ZINC-FINGER NUCLEASES; B-CELL; CANCER-IMMUNOTHERAPY; ADOPTIVE IMMUNOTHERAPY; IMMUNE CHECKPOINTS; MULTIPLE-MYELOMA; CLINICAL-TRIAL; LYMPHOCYTES;
D O I：
10.1016/j.hoc.2017.06.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This article focuses on clinical applications of T cells transduced to express recombinant T-cell receptor and chimeric antigen receptor constructs directed toward hematological malignancies, and considers newer strategies incorporating gene-editing technologies to address graft-versus-host disease and host-mediated rejection. Recent data from clinical trials are reviewed, and an overview is provided of current and emerging manufacturing processes; consideration is also given to new developments in the pipeline.
引用
收藏
页码：913 / +
页数：15
相关论文
共 50 条
  • [1] Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!
    Grant, Melanie L.
    Bollard, Catherine M.
    BLOOD REVIEWS, 2018, 32 (03) : 203 - 224
  • [2] Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies
    Ye, Baixin
    Stary, Creed M.
    Gao, Qingping
    Wang, Qiongyu
    Zeng, Zhi
    Jian, Zhihong
    Gu, Lijuan
    Xiong, Xiaoxing
    JOURNAL OF IMMUNOLOGY RESEARCH, 2017, 2017
  • [3] Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies
    Arunachalam, Arun K.
    Gregoire, Celine
    de Oliveira, Beatriz Coutinho
    Melenhorst, Jan Joseph
    BLOOD REVIEWS, 2024, 68
  • [4] Regulatory Considerations for Approval of Chimeric Antigen Receptor T Cell Therapies for Treatment of Hematological Malignancies
    Elmacken, Mona
    Mahat, Upendra
    Verdun, Nicole
    Fashoyin-Aje, Lola
    BLOOD, 2024, 144 : 7765 - 7766
  • [5] Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies
    Al Hadidi, Samer
    Heslop, Helen E.
    Brenner, Malcolm K.
    Suzuki, Masataka
    MOLECULAR THERAPY, 2024, 32 (08) : 2444 - 2460
  • [6] ANALYSIS OF T-CELL RECEPTOR DELTA CHAIN GENE IN HEMATOLOGICAL MALIGNANCIES
    KIMURA, N
    KIKUCHI, M
    ACTA HAEMATOLOGICA JAPONICA, 1989, 52 (08): : 1471 - 1478
  • [7] CAR T Cell Therapy for Hematological Malignancies
    Xin Yang
    Gao-xiang Wang
    Jian-feng Zhou
    Current Medical Science, 2019, 39 : 874 - 882
  • [8] T cell modulation in immunotherapy for hematological malignancies
    Lin, Chen
    Chen, Shaohua
    Li, Yangqiu
    CELL BIOLOGY AND TOXICOLOGY, 2017, 33 (04) : 323 - 327
  • [9] CAR T Cell Therapy for Hematological Malignancies
    Yang, Xin
    Wang, Gao-xiang
    Zhou, Jian-feng
    CURRENT MEDICAL SCIENCE, 2019, 39 (06) : 874 - 882
  • [10] T cell modulation in immunotherapy for hematological malignancies
    Chen Lin
    Shaohua Chen
    Yangqiu Li
    Cell Biology and Toxicology, 2017, 33 : 323 - 327
12345